MedPath

REDNVIA Co., Ltd.

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

Phase 2
Recruiting
Conditions
Calcific Aortic Valve Disease
Interventions
Drug: Placebo
First Posted Date
2021-12-03
Last Posted Date
2025-06-17
Lead Sponsor
REDNVIA Co., Ltd.
Target Recruit Count
580
Registration Number
NCT05143177
Locations
🇺🇸

Mayo Clinic, AZ, Phoenix, Arizona, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

University of Colorado, Aurora, Colorado, United States

and more 22 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.